Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab and Eribulin in HR+/HER2- Metastatic Breast Cancer
NCT03222856Phase 2Completed
- Sponsor
- MEDSIR
- Start
- Dec 2017
- Primary completion
- Oct 2018
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in breast cancer, sponsored by MEDSIR. Started Dec 2017; status: completed.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03222856.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03222856.